176 related articles for article (PubMed ID: 17725338)
21. In silico prediction of unbound brain-to-plasma concentration ratio using machine learning algorithms.
Chen H; Winiwarter S; Fridén M; Antonsson M; Engkvist O
J Mol Graph Model; 2011 Aug; 29(8):985-95. PubMed ID: 21571561
[TBL] [Abstract][Full Text] [Related]
22. Progress in brain penetration evaluation in drug discovery and development.
Liu X; Chen C; Smith BJ
J Pharmacol Exp Ther; 2008 May; 325(2):349-56. PubMed ID: 18203948
[TBL] [Abstract][Full Text] [Related]
23. Species independence in brain tissue binding using brain homogenates.
Di L; Umland JP; Chang G; Huang Y; Lin Z; Scott DO; Troutman MD; Liston TE
Drug Metab Dispos; 2011 Jul; 39(7):1270-7. PubMed ID: 21474681
[TBL] [Abstract][Full Text] [Related]
24. Screening for phospholipidosis induced by central nervous drugs: comparing the predictivity of an in vitro assay to high throughput in silico assays.
Mesens N; Steemans M; Hansen E; Verheyen GR; Van Goethem F; Van Gompel J
Toxicol In Vitro; 2010 Aug; 24(5):1417-25. PubMed ID: 20430096
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of peritoneal dialysis of tolbutamide in rats under conditions of the plasma unbound fraction being increased.
Makita T; Aiba T; Izuwa Y; Komori Y; Kawasaki H; Kurosaki Y
Biopharm Drug Dispos; 2009 Jan; 30(1):1-8. PubMed ID: 19148953
[TBL] [Abstract][Full Text] [Related]
26. Studies of drug binding to plasma proteins using a variant of equilibrium dialysis.
Eriksson MA; Gabrielsson J; Nilsson LB
J Pharm Biomed Anal; 2005 Jul; 38(3):381-9. PubMed ID: 15925237
[TBL] [Abstract][Full Text] [Related]
27. Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
Fridén M; Bergström F; Wan H; Rehngren M; Ahlin G; Hammarlund-Udenaes M; Bredberg U
Drug Metab Dispos; 2011 Mar; 39(3):353-62. PubMed ID: 21149540
[TBL] [Abstract][Full Text] [Related]
28. Central nervous system distribution kinetics of indinavir in rats.
Hamidi M
J Pharm Pharmacol; 2007 Aug; 59(8):1077-85. PubMed ID: 17725849
[TBL] [Abstract][Full Text] [Related]
29. Development and validation of a pharmacophore-based QSAR model for the prediction of CNS activity.
Gozalbes R; Barbosa F; Nicolaï E; Horvath D; Froloff N
ChemMedChem; 2009 Feb; 4(2):204-9. PubMed ID: 19097128
[TBL] [Abstract][Full Text] [Related]
30. A structure-information approach to the prediction of biological activities and properties.
Hall LH
Chem Biodivers; 2004 Jan; 1(1):183-201. PubMed ID: 17191786
[TBL] [Abstract][Full Text] [Related]
31. In silico modeling of nonspecific binding to human liver microsomes.
Gao H; Yao L; Mathieu HW; Zhang Y; Maurer TS; Troutman MD; Scott DO; Ruggeri RB; Lin J
Drug Metab Dispos; 2008 Oct; 36(10):2130-5. PubMed ID: 18606744
[TBL] [Abstract][Full Text] [Related]
32. [Breaking down barriers--about the art of escorting drugs into the brain].
Kahl U
Lakartidningen; 2003 Jan; 100(3):136-7. PubMed ID: 12596480
[No Abstract] [Full Text] [Related]
33. A generic fast solid-phase extraction high-performance liquid chromatography/mass spectrometry method for high-throughput drug discovery.
Gao L; Cheng X; Zhang J; Burns DJ
Rapid Commun Mass Spectrom; 2007; 21(21):3497-504. PubMed ID: 17922486
[TBL] [Abstract][Full Text] [Related]
34. Current State and Future Perspectives in QSAR Models to Predict Blood- Brain Barrier Penetration in Central Nervous System Drug R&D.
Morales JF; Montoto SS; Fagiolino P; Ruiz ME
Mini Rev Med Chem; 2017; 17(3):247-257. PubMed ID: 27739359
[TBL] [Abstract][Full Text] [Related]
35. Two-dimensional turbulent flow chromatography coupled on-line to liquid chromatography-mass spectrometry for solution-based ligand screening against multiple proteins.
Zhou JL; An JJ; Li P; Li HJ; Jiang Y; Cheng JF
J Chromatogr A; 2009 Mar; 1216(12):2394-403. PubMed ID: 19203758
[TBL] [Abstract][Full Text] [Related]
36. Assessing brain free fraction in early drug discovery.
Read KD; Braggio S
Expert Opin Drug Metab Toxicol; 2010 Mar; 6(3):337-44. PubMed ID: 20102287
[TBL] [Abstract][Full Text] [Related]
37. Differential receptor-mediated drug targeting to the diseased brain.
Rip J; Schenk GJ; de Boer AG
Expert Opin Drug Deliv; 2009 Mar; 6(3):227-37. PubMed ID: 19327042
[TBL] [Abstract][Full Text] [Related]
38. Using molecular docking, 3D-QSAR, and cluster analysis for screening structurally diverse data sets of pharmacological interest.
Santos-Filho OA; Cherkasov A
J Chem Inf Model; 2008 Oct; 48(10):2054-65. PubMed ID: 18816024
[TBL] [Abstract][Full Text] [Related]
39. Role of hydrophobicity on the monoamine receptor binding affinities of central nervous system drugs: a quantitative retention-activity relationships analysis using biopartitioning micellar chromatography.
Quiñones-Torrelo C; Sagrado S; Villanueva-Camañas RM; Medina-Hernández MJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Mar; 801(2):185-98. PubMed ID: 14751786
[TBL] [Abstract][Full Text] [Related]
40. Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function.
Schormann N; Senkovich O; Walker K; Wright DL; Anderson AC; Rosowsky A; Ananthan S; Shinkre B; Velu S; Chattopadhyay D
Proteins; 2008 Dec; 73(4):889-901. PubMed ID: 18536013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
